Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P16112: Variant p.Ile2079Val

Aggrecan core protein
Gene: ACAN
Feedback?
Variant information Variant position: help 2079 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Isoleucine (I) to Valine (V) at position 2079 (I2079V, p.Ile2079Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 2079 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2530 The length of the canonical sequence.
Location on the sequence: help PVTHTPQLFESSGKVSTAGD I SGATPVLPGSGVEVSSVPES The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         PVTHTPQLFESSGKVSTAGDISGATPVLPGSGVEVSSVPES

                              PVTHTPQLFESSGEASASGEISGATPAFPGSGLEASSVPES

Mouse                         SMTYTPRLFEASGDASASGDLGGAVTNFPGSGIEAS-VPEA

Rat                           SMTYTPRLFEASGEASASGDLGGPVTIFPGSGVEAS-VPEG

Bovine                        PVTYTPQLFESSGEASASGDV----PRFPGSGVEVSSVPES

Chicken                       -TIETSTVHETSGEASA----------FPEISIETSTRQEA

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 17 – 2530 Aggrecan core protein
Chain 393 – 2530 Aggrecan core protein 2
Region 1613 – 2277 CS-2
Region 2048 – 2204 Disordered



Literature citations
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2); VARIANTS LEU-864; ILE-930; THR-939; ALA-1080; ALA-1403; ALA-1508; VAL-1765; VAL-2079 AND GLU-2373; Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage.
Dudhia J.; Davidson C.M.; Wells T.M.; Vynios D.H.; Hardingham T.E.; Bayliss M.T.;
Biochem. J. 313:933-940(1996)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 1893-2530 (ISOFORM 2); VARIANTS VAL-2079 AND ARG-2500; A new epidermal growth factor-like domain in the human core protein for the large cartilage-specific proteoglycan. Evidence for alternative splicing of the domain.
Baldwin C.T.; Reginato A.M.; Prockop D.J.;
J. Biol. Chem. 264:15747-15750(1989)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 2051-2530 (ISOFORM 1); VARIANTS VAL-2079 AND ARG-2500;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.